Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of LY01005 vs Zoladex in Prostate Cancer
NCT03450109Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Dec 2017
- Primary completion
- Oct 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Baituowei in prostate cancer (PCa) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Pharmacokinetics (Bio-availability of goserelin) at Day 36. Started Dec 2017; status: completed.
02
Drugs
Baituowei
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03450109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450109.